Showing results (1191-1200 of 1,823) with videos related to

Sort By:
Pageof 183
Journal of Interventional Cardiology|September 14, 2013
Second-generation everolimus-eluting stents compared to first-generation drug-eluting stents in patients treated for multivessel diseaseSa'ar Minha, Israel M Barbash, Danny Dvir, et al.
Journal of Interventional Cardiology|September 17, 2013
Cranio-caudal (transradial) approach for renal artery interventionKintur Sanghvi, John Coppola, Tejas Patel
Journal of Interventional Cardiology|September 17, 2013
The chicken-wing morphology: an anatomical challenge for left atrial appendage occlusionXavier Freixa, Apostolos Tzikas, Arsène Basmadjian, et al.
Journal of Interventional Cardiology|July 22, 2014
RAPSTROM™ first-in-man study long-term results of a biodegradable polymer sustained-release sirolimus-eluting stent in de novo coronary stenosesPrathap Kumar, Ramakrishna Pillai, Madhu Sreedharan, et al.
Journal of Interventional Cardiology|July 22, 2014
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivityThibault Lhermusier, Michael J Lipinski, David Drenning, et al.
Journal of Interventional Cardiology|December 7, 2013
Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosisSeung-Yul Lee, Byeong-Keuk Kim, Jung-Sun Kim, et al.
Journal of Interventional Cardiology|February 20, 2013
MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspirationRafael Romaguera, Joan A Gómez-Hospital, Guillermo Sánchez-Elvira, et al.
Journal of Interventional Cardiology|February 20, 2013
Balloon expandable sheath for transfemoral aortic valve implantation: a viable option for patients with challenging accessZisis Dimitriadis, Werner Scholtz, Lothar Faber, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
Pageof 183